High-Intensity Statins Underused With Atherosclerotic Cardiovascular Disease
![](https://consumer.healthday.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNzcyODAzMC9vcmlnaW4uanBnIiwiZXhwaXJlc19hdCI6MTc1NTk2NDU3OH0.FVT1t-prmrodqcL-9kPIFMznS98Voj9IQo_Wygfc5lI/image.jpg?width=1200&height=800&coordinates=76%2C0%2C77%2C0)
TUESDAY, Sept. 19, 2023 (HealthDay News) -- Among patients with atherosclerotic cardiovascular disease (ASCVD), high-intensity statins are underutilized in routine care, according to a study published online Aug. 2 in Circulation: Cardiovascular Quality and Outcomes.
Ann Marie Navar, M.D., Ph.D., from University of Texas Southwestern Medical Center in Dallas, and colleagues examined use of statins and other lipid-lowering therapy (LLT) and changes in low-density lipoprotein cholesterol (LDL-C) among patients with ASCVD. The analysis included electronic health record-derived data from outpatient visits for 322,153 patients with ASCVD (Cerner Real-World Data from 92 U.S. health systems 2017 through 2018).
The researchers found that 76.1 percent of patients were on statins, with only 39.4 percent on high-intensity statins. Compared with women, men were more likely to receive high-intensity statins (multivariable-adjusted odds ratio [OR], 1.34). Lower odds of statin use were seen with increasing age (OR, 0.79 per five-year increase at 60 years). Compared with patients with coronary heart disease, patients with peripheral artery disease (OR, 0.40) and cerebrovascular disease (OR, 0.75) had lower odds of using high-intensity statins. Most patients (61.3 percent) at baseline had elevated LDL-C (≥70 mg/dL), including 59.8 percent of those on low/moderate-intensity statins and 76.1 percent on no statin. At one year, only 45.3 percent achieved an LDL-C <70 mg/dL. Nonstatin LLT use was low. Among patients on no statin or low/moderate-intensity statin at baseline, at one year, 14.8 and 13.4 percent, respectively, were on high-intensity statins.
"Concerted efforts are needed to address therapeutic inertia for lipid management in patients with ASCVD," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Related Posts
More Health Problems Seen for Latino Children in States With Systemic Inequity
TUESDAY, Aug. 15, 2023 (HealthDay News) -- Latino children residing in states...
Pandemic Has Been Devastating to Mental Health of Disabled Americans
TUESDAY, Feb. 8, 2022 (HealthDay News) -- Loneliness, isolation and fears about...
2019 to 2020 Saw Drop in Number, Rate of Twin Births
WEDNESDAY, Dec. 7, 2022 (HealthDay News) -- The number and rate of twin births...
Psychological Factors Determine Poor Prognostic Outcome in IBD
TUESDAY, April 19, 2022 (HealthDay News) -- For adults with inflammatory bowel...